US Patent

US10953003 — Methods for treating cancer

Formulation · Assigned to Genzyme Corp · Expires 2036-12-14 · 11y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating advanced forms of cancer, such as clear cell renal cell carcinoma, using X4P-001.

USPTO Abstract

The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Drugs covered by this patent

Patent Metadata

Patent number
US10953003
Jurisdiction
US
Classification
Formulation
Expires
2036-12-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.